Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA

Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA is an Italian pharmaceutical company specializing in the development and production of sterile injectable medicines and other pharmaceutical products for diverse therapeutic applications. Founded in 1925 in Como, Italy, Lisapharma produces sterile injectable medicines and operates under a trade sale structure. In July 2019, Shandong Sito Bio-technology Co. , Ltd.

acquired a majority stake in the company from Arcadia SGR and Azimut Libera Impresa for EUR 8. 8 million, representing a strategic pivot in ownership. Lisapharma specializes in the production of sterile injectable medicines, including sterile injectable drugs, non-sterile liquids, semi-solids, and medical devices. Their products are designed to ensure high-quality performance and efficacy, serving both Italian and multinational pharmaceutical companies.

Lisapharma operates in multiple international markets across Europe and Asia, leveraging extensive Marketing Authorizations to meet client needs. In the most recent financial year 2022, Lisapharma reported a revenue of EUR 12,512,459. 30, while the EBITDA for the same year was EUR -67,162. 80.

The company generates revenue primarily through contract manufacturing arrangements and partnerships with international pharmaceutical firms, utilizing a diversified approach to maintain a robust financial structure. Lisapharma aims to expand its footprint in international markets, particularly targeting regions in Asia and Europe for potential growth initiatives. The recent acquisition provides further capital to enhance product development and launch new products tailored to market demands. Following the trade sale in July 2019, the investment will support these expansion strategies and leverage the capabilities of Shandong Sito Bio-technology Co.

, Ltd. to foster growth.